siRNA News and Research

RSS
Small interfering RNA (siRNA), sometimes known as short interfering RNA or silencing RNA, is a class of double-stranded RNA molecules, 20-25 nucleotides in length, that play a variety of roles in biology. Most notably, siRNA is involved in the RNA interference (RNAi) pathway, where it interferes with the expression of a specific gene. In addition to their role in the RNAi pathway, siRNAs also act in RNAi-related pathways, e.g., as an antiviral mechanism or in shaping the chromatin structure of a genome; the complexity of these pathways is only now being elucidated.
MTfp-­siRNA reduces blood vessel infarct, improves overall brain activity in ischemic stroke model

MTfp-­siRNA reduces blood vessel infarct, improves overall brain activity in ischemic stroke model

NIAID partners with Liberian government to test ZMapp drug for Ebola virus disease

NIAID partners with Liberian government to test ZMapp drug for Ebola virus disease

Researchers reveal new understanding of pathobiology behind vestibular schwannoma

Researchers reveal new understanding of pathobiology behind vestibular schwannoma

RXi closes exclusive global license agreement with Hapten Pharmaceuticals for Samcyprone

RXi closes exclusive global license agreement with Hapten Pharmaceuticals for Samcyprone

Dartmouth scientists discover novel cancer resistance mechanism

Dartmouth scientists discover novel cancer resistance mechanism

Changes in current Ebola virus epidemic could potentially interfere with experimental treatments

Changes in current Ebola virus epidemic could potentially interfere with experimental treatments

Precision NanoSystems, Arcturus Therapeutics partner to develop RNA medicines

Precision NanoSystems, Arcturus Therapeutics partner to develop RNA medicines

Arcturus to exhibit new mRNA therapeutics pipeline at two healthcare conferences

Arcturus to exhibit new mRNA therapeutics pipeline at two healthcare conferences

Sirnaomics submits STP705 IND Application to CFDA for skin scar treatment

Sirnaomics submits STP705 IND Application to CFDA for skin scar treatment

New light-triggered strategy can provide accurate control over aptamer-based therapeutics

New light-triggered strategy can provide accurate control over aptamer-based therapeutics

Type 3 interferons and T helper 2 cells: an interview with Grant Gallagher, Managing Director, HUMIGEN

Type 3 interferons and T helper 2 cells: an interview with Grant Gallagher, Managing Director, HUMIGEN

UNC researchers develop new approach to block KRAS oncogene

UNC researchers develop new approach to block KRAS oncogene

MMP-3 disrupts brain/spinal cord barrier, promotes hemorrhage

MMP-3 disrupts brain/spinal cord barrier, promotes hemorrhage

Statement on Ebola epidemic

Statement on Ebola epidemic

RNA molecules in tissue, urine samples can detect prostate cancer

RNA molecules in tissue, urine samples can detect prostate cancer

Avidity NanoMedicines closes $6M convertible note financing, expands investor syndicate

Avidity NanoMedicines closes $6M convertible note financing, expands investor syndicate

Promising new approach for combating colorectal cancer

Promising new approach for combating colorectal cancer

Acromegaly and antisense therapy: an interview with Mark Diamond, CEO Antisense Therapeutics

Acromegaly and antisense therapy: an interview with Mark Diamond, CEO Antisense Therapeutics

Research offers promise for personalized RNA combination therapies to treat lung cancer

Research offers promise for personalized RNA combination therapies to treat lung cancer

Oncothyreon acquires Alpine Biosciences to enable targeted delivery of multiple therapeutic agents

Oncothyreon acquires Alpine Biosciences to enable targeted delivery of multiple therapeutic agents